title: Hereditary Retinal Dystrophy.
abstract: As our understanding of the genetic basis for inherited retinal disease has expanded, gene therapy has advanced into clinical development. When the gene mutations associated with inherited retinal dystrophies were identified, it became possible to create animal models in which individual gene were altered to match the human mutations. The retina of these animals were then characterized to assess whether the mutated genes produced retinal phenotypes characteristic of disease-affected patients. Following the identification of a subpopulation of patients with the affected gene and the development of techniques for the viral gene transduction of retinal cells, it has become possible to deliver a copy of the normal gene into the retinal sites of the mutated genes. When this was performed in animal models of monogenic diseases, at an early stage of retinal degeneration when the affected cells remained viable, successful gene augmentation corrected the structural and functional lesions characteristic of the specific diseases in the areas of the retina that were successfully transduced. These studies provided the essential proof-of-concept needed to advance monogenic gene therapies into clinic development; these therapies include treatments for: Leber's congenital amaurosis type 2, caused by mutations to RPE65, retinoid isomerohydrolase; choroideremia, caused by mutations to REP1, Rab escort protein 1; autosomal recessive Stargardt disease, caused by mutations to ABCA4, the photoreceptor-specific ATP-binding transporter; Usher 1B disease caused by mutations to MYO7A, myosin heavy chain 7; X-linked juvenile retinoschisis caused by mutations to RS1, retinoschisin; autosomal recessive retinitis pigmentosa caused by mutations to MERTK, the proto-oncogene tyrosine-protein kinase MER; Leber's hereditary optic neuropathy caused by mutations to ND4, mitochondrial nicotinamide adenine dinucleotide ubiquinone oxidoreductase (complex I) subunit 4 and achromatopsia, caused by mutations to CNGA3, cyclic nucleotide-gated channel alpha 3 and CNGB3, cyclic nucleotide-gated channel beta 3. This review includes a tabulated summary of treatments for these monogenic retinal dystrophies that have entered into clinical development, as well as a brief summary of the preclinical data that supported their advancement into clinical development.
authors.affiliation: Envision Consulting LLC, Ocean City, NJ, USA. ThomasCHohman@gmail.com.
authors.forename: Thomas C
authors.initials: TC
authors.lastname: Hohman
mesh_terms: D003117:Color Vision Defects / Q000235:genetics / Q000628:therapy; D006801:Humans; D057130:Leber Congenital Amaurosis / Q000235:genetics / Q000628:therapy; D029242:Optic Atrophy, Hereditary, Leber / Q000235:genetics / Q000628:therapy; D000090063:Proto-Oncogene Mas; D058499:Retinal Dystrophies / Q000235:genetics* / Q000628:therapy*; D012174:Retinitis Pigmentosa / Q000235:genetics / Q000628:therapy
keywords: ABCA4; Achromatopsia; Adeno-associated viral vectors; CNGA3; CNGB3; Choroideremia; Gene augmentation; Gene therapies; Inherited retinal degenerative dystrophies; Leber’s congenital amaurosis; Leber’s hereditary optic neuropathy; Lentiviral vector; MERTK; MYO7; ND1; ND4; ND6; REP1; RPE65; RS1; Retinitis pigmentosa; Retinoschisin; Stargardt disease; Usher disease; X-linked juvenile retinoschisis